Phases, active trials: Phase 1: 37, Phase 1/2: 21, Phase 2: 35, Phase 2/3: 3, Phase 3: 62, Phase 4: 10, No phase listed: 4
GSK's pipeline spans oncology, specialty medicines, and vaccines. In oncology, dostarlimab (Jemperli), a PD-1 inhibitor with approval in dMMR endometrial cancer, is expanding into multiple solid tumor indications. Their BCMA-targeting ADC, belantamab mafodotin (Blenrep), initially approved and then voluntarily withdrawn pending new trial data, is being re-evaluated in combination trials in multiple myeloma. In gynecologic oncology, niraparib (Zejula) for ovarian cancer is progressing through combination trials. GSK's vaccine pipeline is one of the industry's strongest. Shingrix (shingles), Arexvy (RSV), and next-generation pandemic influenza vaccines represent major development investments. In respiratory/inflammation, Nucala (mepolizumab, IL-5) is expanding across eosinophilic conditions.
- Oncology (PD-1, BCMA/ADC, PARP inhibitor)
- Vaccines (RSV, influenza, meningococcal)
- Respiratory / inflammation (IL-5, COPD)
- HIV (long-acting cabotegravir)
- Rare disease
- Jemperli (dostarlimab): PD-1, gynecologic/dMMR cancers
- Blenrep (belantamab mafodotin): BCMA ADC, myeloma (combination trials)
- Zejula (niraparib): PARP inhibitor, ovarian cancer
- Nucala (mepolizumab): IL-5, eosinophilic asthma/EGPA
- Arexvy: RSV vaccine, adults 60+
- GSK3745417: STING agonist, solid tumors
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other… NCT06885034 | Primary completion moved at least 11 months later Enrollment reduced 23% | Recruiting |
25 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX)… NCT06567782 | Nov 23, 2026 · Estimated | Phase 2 |
17 more on the Completions page. See the calendar →
Monitor the GSK (GlaxoSmithKline) pipeline daily
Get a daily digest when GSK (GlaxoSmithKline) registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Multiple Myeloma | 20 |
| Asthma | 12 |
| Neoplasms | 8 |
| Pulmonary Disease, Chronic Obstructive | 8 |
| Gastrointestinal Neoplasms | 7 |
| Hepatitis B | 6 |
| Neoplasms, Endometrial | 6 |
| Ovarian Neoplasms | 5 |
GSK's Jemperli re-expansion program, building on the dMMR endometrial approval into broader MSI-high/dMMR tumor types and combination regimens, generates consistent new oncology registrations. Their PARP inhibitor niraparib combination trials are closely followed in gynecologic oncology. The belantamab combination re-introduction is one of the most watched programs in multiple myeloma.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to GSK (GlaxoSmithKline)'s registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: GSK (GlaxoSmithKline) may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your GSK (GlaxoSmithKline) pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With… NCT06613698 | Recruiting | Study completion pushed from Mar 7, 2028 to Mar 2, 2029 | 2026-11-14 |
| Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and… NCT04246047 | Active, Not Recruiting | Study completion pushed from Jun 30, 2028 to Oct 8, 2029 | 2026-11-14 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With… NCT07782996 | Recruiting | Trial sites expanded: 7 → 13 locations | 2026-11-13 |
| A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus… NCT06576271 | Active, Not Recruiting | Trial sites reduced: 28 → 23 locations | 2026-11-13 |
| REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on… NCT06041386 | Active, Not Recruiting | Study completion moved earlier from Jun 14, 2028 to Mar 31, 2027 | 2026-11-11 |
Each trial page shows every change DataLookout has recorded for that trial.